Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.76 |
| ▸ | SYK | P43405 | 3/20 | 0.76 |
| ▸ | RET | P07949 | 4/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 6/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.63 |
| ▸ | FLT3 | P36888 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | LTK | P29376 | 2/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.63 |
| ▸ | CDK7 | P50613 | 2/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.63 |
| ▸ | MST1R | Q04912 | 2/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420371 | 1.00 | NTRK1 (0.76) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5182676 | 0.86 | NTRK1 (1.00) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5182671 | 0.86 | NTRK1 (1.00) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5843067 | 0.86 | NTRK1 (0.80) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5181885 | 0.86 | NTRK1 (0.80) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5181556 | 0.85 | NTRK1 (0.76) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5181559 | 0.85 | NTRK1 (0.76) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5430091 | 0.81 | SRC (0.54) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL5183887 | 0.81 | SRC (0.54) | NTRK1SYKRETNTRK3NTRK2 | |
| SCHEMBL6393548 | 0.80 | SRC (0.59) | NTRK1SYKRETNTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| US-7186739-B2 | Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | IMMUPHARMA (FRANCE) SA (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-7060845-B2 | Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | NEOMPS (FR) | 2006-06-13 | — | — | US | disclosed |
| US-20050159584-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-07-21 | — | — | US | disclosed |
| US-20050159585-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-07-21 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020143191-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | UREKA SARL (FR) | 2002-10-03 | — | — | US | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159584-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ASNS, ACMSD | NTRK1 1974/4885SYK 3648/4885RET 3070/4885 |
| US-20050159585-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ASNS, ACMSD | NTRK1 1974/4885SYK 3648/4885RET 3070/4885 |
| US-20020143191-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ACMSD, PROC | NTRK1 1866/4885SYK 3200/4885RET 2962/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | NTRK1 664/4885SYK 744/4885RET 487/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | NTRK1 1206/4885SYK 878/4885RET 1635/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | NTRK1 1206/4885SYK 878/4885RET 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.